• Home
    • Overview/Our mission
    • News and Events
    • Stock Quote
  • About us
    • At a glance
    • Our values
    • Management team
    • Board of Directors
    • Scientific Advisors
      • Cell Therapy Scientific Advisory Board
      • Glioblastoma Scientific Advisory Board
  • Science
    • NK Cell Derived Allogeneic Therapies
      • CHM 0201 (CORE-NK Platform)
      • CHM 0301 (Next Generation CORE-NK Platform)
      • CHM 1301 (CLTX CAR-NK)
      • CHM 2301 (CDH17 CAR-NK)
      • CHM 3301 (Undisclosed CAR-NK)
    • T Cell Derived Autologous Therapies
      • CHM 1101 (CLTX CAR T)
      • CHM 2101 (CDH17 CAR T)
    • Collaborations
    • About Cell Therapy
  • Pipeline
    • Overview
    • Clinical Trials
      • CHM 1101 (CLTX CAR T)
      • CHM 0201 (CORE-NK Platform)
    • Abstracts and Publications
  • News and Events
    • Press releases
    • Events and presentations
    • Media Coverage
    • Media Resources
  • Investors
    • Corporate Profile​
    • Investor News and Events
      • Annual Report
      • Press releases
      • Events and presentations
      • Analyst Coverage
      • Shareholder Newsletters
    • Stock information
      • Stock quote and chart
      • Historical price lookup
    • Corporate Governance
      • Corporate Charters
      • Corporate Policies
    • Resources
      • Investor Q and A
      • Email alerts
      • Investor Contacts
  • Careers
Menu
  • Home
    • Overview/Our mission
    • News and Events
    • Stock Quote
  • About us
    • At a glance
    • Our values
    • Management team
    • Board of Directors
    • Scientific Advisors
      • Cell Therapy Scientific Advisory Board
      • Glioblastoma Scientific Advisory Board
  • Science
    • NK Cell Derived Allogeneic Therapies
      • CHM 0201 (CORE-NK Platform)
      • CHM 0301 (Next Generation CORE-NK Platform)
      • CHM 1301 (CLTX CAR-NK)
      • CHM 2301 (CDH17 CAR-NK)
      • CHM 3301 (Undisclosed CAR-NK)
    • T Cell Derived Autologous Therapies
      • CHM 1101 (CLTX CAR T)
      • CHM 2101 (CDH17 CAR T)
    • Collaborations
    • About Cell Therapy
  • Pipeline
    • Overview
    • Clinical Trials
      • CHM 1101 (CLTX CAR T)
      • CHM 0201 (CORE-NK Platform)
    • Abstracts and Publications
  • News and Events
    • Press releases
    • Events and presentations
    • Media Coverage
    • Media Resources
  • Investors
    • Corporate Profile​
    • Investor News and Events
      • Annual Report
      • Press releases
      • Events and presentations
      • Analyst Coverage
      • Shareholder Newsletters
    • Stock information
      • Stock quote and chart
      • Historical price lookup
    • Corporate Governance
      • Corporate Charters
      • Corporate Policies
    • Resources
      • Investor Q and A
      • Email alerts
      • Investor Contacts
  • Careers
Linkedin-in Youtube Twitter Envelope
Publications

A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells Incorporating a Chlorotoxin Tumor-targeting Domain for Patients with MMP2+ Recurrent or Progressive Glioblastoma

Read More »
August 2021
Publications

Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma

Read More »
March 2020
Publications

Current Biochemical Applications and Future Prospects of Chlorotoxin in Cancer Diagnostics and Therapeutics

Read More »
November 2019
Publications

Glioblastoma multiforme targeted therapy: The Chlorotoxin story

Read More »
November 2016
Publications

Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin

Read More »
August 2002
Sign-up to our mailing list to receive all the latest news from Chimeric Therapeutics
 
Please fill out our form for Investor Relations Inquiries
Investor Contacts
Linkedin-in Youtube Twitter Envelope